QuatRx Pharmaceuticals  www.quatrx.com
QuatRx Pharmaceuticals Company is a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. We currently have four product candidates in clinical development. Our two lead compounds, Ophena™ and fispemifene, treat hormone deficiencies that result from aging in women and men.
Ophena™ (ospemifene), our treatment for vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women, is in a second Phase III pivotal study having successfully completed an initial pivotal Phase III study.
Fispemifene, our treatment for testosterone deficiency and other conditions in men, is in Phase II clinical testing.
Sobetirome (QRX-431), our product candidate for the treatment of dyslipidemia, is in Phase I clinical testing.
Asord™ (becocalcidiol), our topical product candidate for the treatment of psoriasis, is in Phase II clinical trials through our licensee Galderma.
Our management team has extensive experience in pharmaceutical development, particularly in endocrine and cardiovascular therapies, having participated in over 60 clinical development programs in their careers. Our management team has contributed to over 30 programs involving approved drugs, ten of which reached annual sales in excess of $1 billion and include the world’s best selling pharmaceutical product, Lipitor.